Angiotensin II Stimulates the NLRP3 Inflammasome to Induce Podocyte Injury and Mitochondrial Dysfunction

Min Zhao^{a, b} Mi Bai^{a-c} Guixia Ding^{a, b} Yue Zhang^{a, b} Songming Huang^{a, b}
Zhanjun Jia^{a-c} Aihua Zhang^{a-c}

^aDepartment of Nephrology, State Key Laboratory of Reproductive Medicine, Children's Hospital of Nanjing Medical University, Nanjing, China; ^bJiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing, China;

^cNanjing Key Laboratory of Pediatrics, Nanjing, China

Keywords

Angiotensin II · Mitochondrial dysfunction · NLRP3 inflammasome · Podocyte

Abstract

Background: We previously reported that the NLRP3 inflammasome played an important role in mediating the podocyte injury induced by aldosterone. However, more studies on the role of the NLRP3 inflammasome in the pathogenesis of podocytopathy are still required. The present study was undertaken to study the role of the NLRP3 inflammasome in angiotensin II (Ang II)-induced podocyte injury, as well as the potential mechanisms. **Methods:** In this study, we used an Ang II infusion model in NLRP3^{-/-} mice. In cultured podocytes, we used siRNA to silence NLRP3; then we treated the podocytes with Ang II. **Results:** Following Ang II treatment, we found that the NLRP3 inflammasome was significantly activated in line with mitochondrial dysfunction in a dose- and time-dependent manner. Silencing NLRP3 by siRNA transfection ameliorated podocyte apoptosis, attenuated the loss of the podocyte proteins nephrin and podocin, and protected mitochondrial function. Ang II infusion activated the NLRP3 inflammasome, caused albuminuria, and induced

podocyte damage, which was all blocked in the NLRP3^{-/-} mice. At the same time, NLRP3 deletion also ameliorated the mitochondrial dysfunction induced by Ang II infusion. However, the deletion of NLRP3 did not affect the Ang II hypertension. **Conclusion:** Taken together, these results demonstrate an important role of the NLRP3 inflammasome in mediating Ang II-induced podocyte injury and mitochondrial dysfunction, suggesting that the NLRP3 inflammasome might be an effective therapeutic target against podocytopathy.

© 2018 S. Karger AG, Basel

Introduction

Angiotensin II (Ang II), a major bioactive product of the renin-angiotensin system, plays a critical role in maintaining blood pressure and fluid homeostasis [1, 2]. However, Ang II also contributes to the pathogenesis of various diseases, mainly by inducing oxidative stress, inflammation, cholesterol accumulation, and fibrosis [3–5]. Moreover, accumulating evidence shows that inflammation plays an important role in the development and pro-

Min Zhao and Mi Bai contributed equally to this work.

gression of renal diseases [6–8]. For example, a previous study reported that Ang II could induce inflammation in renal tubular cells [9].

The NLRP3 (NOD-like receptor 3) inflammasome is well characterized among the members of the NLR family. A functional inflammasome complex is formed through CARD-CARD interaction of ASC (apoptosis-associated speck-like protein containing carboxy-terminal CARD) with procaspase-1. Activation of the NLRP3 inflammasome finally triggers the maturation of IL-1 β and IL-18 via activated caspase-1 [10, 11]. Studies from our and other groups suggest that activation of the NLRP3 inflammasome is involved in renal tubular and podocyte injury induced by albuminuria or aldosterone [12–15]. However, the role of the NLRP3 inflammasome in Ang II-induced podocyte injury has not been defined.

Mitochondria are complex intracellular organelles that are responsible for various metabolic activities including energy production via oxidative phosphorylation. Mitochondrial dysfunction is characterized by increased reactive oxygen species production, the accumulation of impaired mtDNA, and progressive respiratory chain dysfunction. Growing evidence indicates that mitochondrial dysfunction is involved in podocyte injury [16]. In agreement with these results, we found in our previous study [17] that mitochondrial dysfunction is an early event in podocyte injury. Recently, a study reported Ang II could induce mitochondrial dysfunction in skeletal muscle [18]. However, the role of mitochondrial dysfunction in Ang II-induced podocyte injury remains elusive.

In the present study, using a siRNA approach and NLRP3^{-/-} mice, we show that NLRP3 inflammasome activation contributes to Ang II-induced podocyte injury and mitochondrial dysfunction. These findings not only reveal a novel mechanism mediating Ang II-induced podocyte injury but also offer a new target for the treatment of podocytopathy.

Methods

Reagents and Antibodies

Newborn bovine serum was purchased from Gibco (Gibco, USA). Ang II and murine interferon- γ were obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against NLRP3, podocin, and nephrin were from Abcam (Cambridge, MA, USA). Anti-caspase-1 and anti- β -actin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Podocyte Culture

Conditionally immortalized murine MPC5 podocyte clonal cells (kindly provided by Peter Mundel at the Icahn School of Med-

Table 1. Primer sequences for quantitative real-time PCR

Gene symbol	Primer sequence 5'–3'
NLRP3	GTGGTGACCCTCTGTGAGGT TCTTCCTGGAGCGCTTCTAA
Caspase-1	ACAAGGCACGGGACCTATG TCCCAGTCAGTCCTGGAAATG
Nephrin	ATGGGAGCTAAGGAAGCCACA CCACACCACAGCTTAACTGTC
Podocin	TGCTACTACCGCATGGAAAATG CTGCATCTAAGGCAACCTTTACA
mtDNA	ATCCTCCCAGGATTTGGAAT ACCGGTAGGAATTGCGATAA
18S rRNA	TTCGGAAGTGAAGGCCATGATT TTTCGCTCTGGTCCGTCTTG
GAPDH	AATGGATTTGGACGCATTGGT TTTGCACTGGTACGTGTTGAT

icine at Mount Sinai through Dr. Jie Ding at Peking University) were cultured and induced to differentiate as described previously [19]. The cells were maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum, 100 U/mL penicillin G, 10 U/mL recombinant murine interferon- γ , and 100 mg/mL streptomycin in a 5% CO₂ atmosphere at 33 °C. Podocytes were maintained without interferon- γ at 37 °C for 10–14 days to induce differentiation before the experiments.

siNLRP3 Transfection

NLRP3 siRNA and vehicle siRNA were from GenePharma (China). Podocytes were cultivated to 40–60% confluence in culture medium containing no penicillin or streptomycin. The cells were transfected with 50 nM NLRP3 siRNA or control siRNA 24 h before Ang II treatment using siRNA-Mate (GenePharma) according to the manufacturer's instructions. The siRNA sequences were as follows: siNLRP3, 5'-CGGCCUUACUCAAUCUGUTT-3' and 5'-ACAGAUUGAAGUAAGGCCGTT-3'.

Animals

The study protocols were reviewed and approved by the Institutional Animal Care and Use Committee at Nanjing Medical University, China. Nlrp3^{-/-} mice on a C57BL/6J background were purchased from The Jackson Laboratory (Sacramento, CA, USA). In brief, heterozygous littermates were bred to generate homozygous KO mice and wild-type (WT) littermate controls; 10- to 12-week-old male mice (22–26 g) were used in our study. All mice were maintained on a 12-h light-dark cycle in a temperature-controlled (19–21 °C) room and were fed standard rodent chow.

Animal Model of Ang II Infusion

Male NLRP3^{-/-} (KO) and WT mice aged 10–12 weeks and weighing 22–26 g were treated with Ang II using subcutaneously implanted osmotic minipumps (ALZET; DURECT, Cupertino,

Fig. 1. Angiotensin II (Ang II) activated the NLRP3 inflammasome and induced podocyte injury. Cells were grown on 6-well plates until 80% confluence, then treated with different doses of Ang II (10^{-8} , 10^{-7} , and 10^{-6} mol/L) for 24 h. **a** Western blotting analyses of NLRP3, caspase-1, nephrin, and podocin expression. **b**, **c** qRT-

PCR analysis of NLRP3 and caspase-1 expression. **d** ELISA analysis of IL-18 levels in the supernatant of cultured cells. **e**, **f** qRT-PCR analyses of nephrin and podocin expression. Data are presented as means $\pm$ SE ($n = 6$). * $p < 0.05$ vs. control (0 mol/L).

CA, USA). The pumps were placed by making an incision in the right flank region under light anesthesia with 3% isoflurane; they delivered a continuous infusion of Ang II (300 ng/kg/min) for 28 days. All mice were maintained on a 12-h light-dark cycle in a temperature-controlled (19–21°C) room. They were fed standard rodent chow and had free access to drinking water.

Apoptosis Analysis

Hoechst 33258 Staining. Podocytes were grown on glass coverslips for measurement of apoptosis. After treatment, the podocytes were stained with Hoechst 33258 and viewed by fluorescence microscopy.

Annexin V-Fluorescein Isothiocyanate Conjugated with Propidium Iodide. After treatment, the podocytes were seeded into 6-well plates, and apoptosis was quantified by flow cytometry using annexin V-fluorescein isothiocyanate and propidium iodide double staining (annexin V-fluorescein isothiocyanate apoptosis Q18 detection kit; BD Biosciences), according to the manufacturer's instructions.

TUNEL Assay in Cultured Podocytes. Apoptotic cell death was determined using TUNEL staining with an In Situ Cell Death Detection Kit (Roche Molecular Biochemicals, Mannheim, Germany), following the manufacturer's protocol. Morphological changes in podocytes undergoing apoptosis were then detected by counterstaining them with Hoechst 33258. The slides were examined by confocal microscopy.

Fig. 2. Angiotensin II (Ang II) induced podocyte apoptosis and mitochondrial dysfunction. Cells were grown on 6-well plates until 80% confluence, then treated with Ang II (10^{-6} mol/L) for different periods of time (0, 2, 4, 6, 12, and 24 h) or at different doses of Ang II. **a** Hoechst 33258 staining. The arrows indicate chroma-

tin condensation and fragmentation. **b** Cell apoptosis after Ang II treatment detected by flow cytometry. **c, f** qRT-PCR analysis of mtDNA copy number. **d, g** ATP production. **e, h** Quantitation of JC-1 fluorescence by flow cytometry. Data are presented as means $\pm$ SE ($n = 6$). * $p < 0.05$ vs. control (0 mol/L).

Western Blotting

Podocytes or renal tissue were lysed in protein lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 10 mmol/L EDTA, 1% Triton X-100, 200 mmol/L sodium fluoride, and 4 mmol/L sodium orthovanadate as protease inhibitors; pH 7.5) for 15 min on ice. Protein was extracted. Immunoblotting was performed with primary antibodies against NLRP3 (1:500), nephrin (1:1,000), podocin (1:1,000), caspase-1 (1:250), or β -actin (1:1,000), followed by the addition of horseradish peroxidase-labelled secondary antibodies. The blots were visualized with Amersham ECL Detection Systems (Amersham, UK). Densitometric analysis was performed using Quantity One Software (Bio-Rad).

Quantitative Real-Time PCR and Reverse Transcription PCR

Total RNA was isolated from MPC cells and the renal cortex using a TRIzol Total RNA Isolation Kit (Invitrogen) according to the manufacturer's protocol. The RNA was eluted with RNase-free water. Reverse transcription was performed using the Superscript III RT Kit (Invitrogen) according to the manufacturer's protocols. Briefly, the reactions were incubated at 65°C for 5 min and then at 50°C for 60 min. Total DNA from cultured podocytes and renal tissue were extracted with a DNeasy Tissue Kit (QIAGEN Science). Oligonucleotides were designed with Primer3 software (available at http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and synthesized at Invitrogen (the primer sequences are shown in Table 1). Real-time PCR amplification was performed using the SYBR Green Master Mix (Roche) and the Prism 7500 Real-Time PCR Detection System (Applied Biosystems). The cycling condi-

Fig. 3. Silencing NLRP3 protected angiotensin II (Ang II)-induced podocyte injury. Cells were grown on 6-well plates until 30% confluence and transfected with siNLRP3 for 24 h, then treated with Ang II (10^{-6} mol/L) for another 24 h. **a** Western blotting analysis of NLRP3 and nephrin. **b** qRT-PCR analysis of NLRP3. **c** ELISA analysis of the IL-18 concentration in the medium of cultured cells.

Podocytes were incubated with Ang II for 24 h, and the medium was collected to detect IL-18 by ELISA. **d** qRT-PCR analysis of caspase-1. **e** qRT-PCR analysis of podocin. **f** qRT-PCR analysis of nephrin. Data are presented as means $\pm$ SE ($n = 6$). * $p < 0.05$ vs. vehicle group; # $p < 0.05$ vs. Ang II-treated group.

tions were 95°C for 10 min followed by 40 repeats of 95°C for 15 s and 60°C for 1 min. Relative amounts of mtDNA copy numbers were normalized to 18S ribosomal RNA levels encoded by the nuclear DNA, and mRNA was normalized to GAPDH and calculated using the delta-delta method from threshold cycle numbers.

ATP Content Measurement

ATP levels in the podocytes were determined with a luciferase-based bioluminescence assay kit (Sigma-Aldrich) in a FLUOstar Optima reader according to the manufacturer's instructions.

Mitochondrial Membrane Potential

The mitochondrial membrane potential (MMP) of podocytes was monitored using JC-1, a MMP-sensitive fluorescent dye, as described previously [20]. Briefly, podocytes were washed twice with PBS and incubated in the dark with JC-1 probe (7.5 mmol/L; 30 min at 37°C). The cells were washed with JC-1 washing buffer,

and fluorescence was detected by flow cytometry. The relative MMP was calculated using the ratio of J-aggregate/monomer (590/520 nm). Values are expressed as fold change in J-aggregate/monomer fluorescence over control cells.

Blood Pressure Measurement

Systolic blood pressure of the mice was measured by the tail-cuff method, using a Visitech BP-2000 Blood Pressure Analysis System (Visitech Systems, Apex, NC, USA).

Transmission Electron Microscopy

Fresh kidney tissues were fixed in 1.25% glutaraldehyde/0.1 mol/L phosphate buffer and postfixed in 1% OsO_4 /0.1 mol/L phosphate buffer. Ultrathin sections (60 nm) were cut on a microtome, placed on copper grids, stained with uranyl acetate and lead citrate, and examined under an electron microscope (JEM-1010; JEOL Ltd., Tokyo, Japan).

Fig. 4. Silencing of NLRP3 attenuated angiotensin II (Ang II)-induced podocyte apoptosis. Cells were grown on 6-well plates until 30% confluence and transfected with siNLRP3 for 24 h, then treated with Ang II (10^{-6} mol/L) for another 24 h. **a** TUNEL staining.

The arrows indicate TUNEL-positive signals. **b** Quantitation of podocyte apoptosis, which was determined by flow cytometry. Data are presented as means $\pm$ SE ($n = 6$). * $p < 0.05$ vs. vehicle group; # $p < 0.05$ vs. Ang II-treated group.

Analysis of Urinary Albumin

The urinary concentration of albumin was determined using enzyme-linked immunosorbent assay kits from Exocell (Philadelphia, PA, USA).

Statistical Analysis

Data are presented as means $\pm$ SE. Statistical analysis was performed using ANOVA followed by a Bonferroni posttest or unpaired Student t test. $p < 0.05$ was considered statistically significant.

Results

Ang II Activated the NLRP3 Inflammasome and Induced Podocyte Injury

We firstly examined the effect of Ang II on activation of the NLRP3 inflammasome. As shown by the data, Ang II induced NLRP3 inflammasome activation as evidenced

by the increments in NLRP3, active caspase-1, and IL-18 in a dose-dependent manner (Fig. 1a–d). Meanwhile, Ang II dose-dependently downregulated the expression of the podocyte proteins nephrin and podocin (Fig. 1e, f) accompanied by enhanced podocyte apoptosis (Fig. 2a, b). These results suggest that NLRP3 inflammasome activation might be involved in Ang II-induced podocyte injury.

Ang II Induced Mitochondrial Dysfunction in Podocytes

To evaluate the effect of the Ang II challenge on mitochondrial function, we assessed the MMP, ATP levels, and mtDNA copy number. As shown in Figure 2c–h, Ang II could induce a reduction in mtDNA copy number, ATP content, and MMP in podocytes in a dose- and time-dependent manner. These results demonstrate that Ang II induced mitochondrial dysfunction in podocytes.

Fig. 5. Knockdown of NLRP3 attenuated angiotensin II (Ang II)-induced mitochondrial dysfunction. Cells were grown on 6-well plates until 30% confluence and transfected with siNLRP3 for 24 h, then treated with Ang II (10^{-6} mol/L) for another 24 h. **a** Representative images of JC-1 staining. **b** Quantitation of JC-1 fluores-

cence by flow cytometry. **c** ATP content was detected as described in the Methods section. **d** qRT-PCR analysis of the mtDNA copy number. Data are presented as means $\pm$ SE ($n = 6$). * $p < 0.05$ vs. vehicle group; # $p < 0.05$ vs. Ang II-treated group.

Silencing NLRP3 Ameliorated Ang II-Induced Podocyte Injury

To define the role of NLRP3 inflammasome activation in Ang II-induced podocyte injury, we silenced NLRP3 through the transfection of siNLRP3 in podocytes. Strikingly, invalidation of NLRP3 significantly reversed the downregulation of the podocyte proteins nephrin and podocin (Fig. 3e, f) in line with a blockade of NLRP3 inflammasome activation in response to Ang II (Fig. 3a–d). Meanwhile, as shown in Figure 4, Ang II-induced podocyte apoptosis was markedly attenuated by siNLRP3. These results demonstrate that activation of the NLRP3 inflammasome contributed to Ang II-induced podocyte injury.

Silencing NLRP3 Attenuated Ang II-Induced Mitochondrial Dysfunction in Podocytes

We then explored the effect of NLRP3 on mitochondrial dysfunction in podocytes challenged with Ang II. As shown in Figure 5, Ang II strikingly impaired mitochondrial function, which was partially but significantly ameliorated by siNLRP3 as evidenced by restoration of the MMP, ATP content, and mtDNA copy number, indicating that Ang II-induced mitochondrial dysfunction in podocytes might be mediated by activation of the NLRP3 inflammasome.

Deletion of NLRP3 Improved Ang II-Induced Podocyte Injury and Mitochondrial Dysfunction in Mice

We further investigated whether deletion of NLRP3 could inhibit Ang II-induced podocyte injury and mito-

Fig. 6. Deletion of NLRP3 blocked activation of the NLRP3 inflammasome in angiotensin II (Ang II)-treated murine kidneys. **a** Systolic blood pressure after Ang II infusion in wild-type (WT) and NLRP3^{-/-} mice determined by the tail-cuff method. **b** Immunohistochemistry of NLRP3 in the kidneys. **c** qRT-PCR analysis of

NLRP3 in the kidneys. **d** qRT-PCR analysis of caspase-1 in the kidneys. **e** IL-18 levels in the blood. Data are presented as means $\pm$ SE ($n = 8$). * $p < 0.05$ vs. vehicle group; # $p < 0.05$ vs. Ang II-treated group.

chondrial dysfunction in mice. First, we measured the blood pressure using the tail-cuff method. As shown in Figure 6a, both genotypes displayed a similar hypertensive response after Ang II infusion. At the same time, Ang II infusion enhanced the expression of NLRP3 in glomeruli (Fig. 6b, c) in line with increments in caspase-1 in the kidneys (Fig. 6d) and IL-18 in the blood (Fig. 6e). Strikingly, NLRP3 deletion blocked the upregulation of renal caspase-1 and the increase in blood IL-18 levels (Fig. 6d, e), suggesting a blockade of NLRP3 inflammasome activation.

Next, we found that the output of urinary albumin was significantly blunted in NLRP3^{-/-} mice as compared with the WT controls following Ang II infusion for 28 days (Fig. 7a). Consistent with the attenuation of albuminuria, we observed that the reduction of podocin and nephrin was partly reversed in NLRP3^{-/-} mice (Fig. 7c–e), and the podocyte foot process fusion determined by electron microscopy was also mitigated in NLRP3^{-/-} mice following 4-week Ang II infusion (Fig. 7b).

Finally, we observed the mitochondrial morphology of the podocytes in kidneys of mice after 4-week Ang II in-

fusion, as well as the mitochondrial DNA copy number. As shown in Figure 8, NLRP3^{-/-} mice exhibited an obvious improvement of the abnormality of their mitochondrial morphology and of the loss in mtDNA copy number. Taken together, these in vivo data demonstrate that deletion of NLRP3 in mice protects the podocytes against Ang II-induced injury, possibly to some extent through a mitochondrial mechanism.

Discussion

Podocyte injury occurs in all glomerular diseases [21]. In the present study, using cells and animals, we investigated the contribution of the NLRP3 inflammasome in the pathogenesis of podocyte injury and mitochondrial dysfunction resulting from Ang II infusion. The findings indicated that NLRP3 inflammasome activation was attributable to the Ang II-induced podocyte apoptosis, loss of the slit diaphragm proteins nephrin and podocin, and mitochondrial dysfunction, which would lead to proteinuria.

Fig. 7. Deletion of NLRP3 attenuated angiotensin II (Ang II)-induced kidney injury. **a** Urinary albumin output. **b** Representative images of podocyte foot process morphology by electron microscopy. **c** Western blotting analysis of nephrin and podocin. **d** qRT-

PCR analysis of nephrin. **e** qRT-PCR analysis of podocin. Data are presented as means $\pm$ SE ($n = 8$). * $p < 0.05$ vs. vehicle group; # $p < 0.05$ vs. Ang II-treated group. ACR, albumin/creatinine ratio; WT, wild type.

Ang II, as the strongest effector molecule in the RAS system, was reported to be involved in the pathogenesis of various kidney diseases through inducing renal inflammation [22, 23]. Recent evidence demonstrated that the NLRP3 inflammasome played a detrimental role in kidney diseases [24–26]. Our previous study also showed that the NLRP3 inflammasome was involved in aldosterone-induced podocyte injury and 5/6 nephrectomy-related renal tubular damage [12, 13, 27]. In the present study, we found that Ang II activated the NLRP3 inflammasome in podocytes and that NLRP3 silencing attenuated the Ang II-induced podocyte apoptosis and loss of the podocyte-specific proteins nephrin and podocin. In vivo, albuminuria was partly mitigated in NLRP3^{-/-} mice, which is in agreement with the finding by Wen et al. [28]. We further found that the loss of nephrin and podocin and the podocyte foot process fusion were ameliorated in NLRP3^{-/-} mice. These data highly suggest a pathogenic role of the NLRP3 inflammasome in Ang II-mediated podocyte injury. However, systemic deletion of NLRP3

could not fully address the contribution of podocyte NLRP3 in mediating the Ang II-induced podocyte injury. In the future, studies in animals with podocyte-specific deletion of NLRP3 are still needed.

Over the past decade, many studies have shown that Ang II can activate NADPH oxidases and increase reactive oxygen species production to further participate in different pathophysiological processes including the promotion of mitochondrial dysfunction [29–31]. However, the exact mechanism is not yet conclusively elucidated. Previous studies from our and other groups demonstrated that albumin-induced mitochondrial dysfunction was mediated by NLRP3 inflammasome activation in tubular epithelial cells [14, 32]. However, the relationship between mitochondrial dysfunction and activation of the NLRP3 inflammasome in response to an Ang II challenge in podocytes remains unclear. In cells, our data showed that mitochondrial function was significantly impaired in podocytes by Ang II as demonstrated by reduction of the mtDNA copy number, ATP content, and MMP. Knock-

Fig. 8. Deletion of NLRP3 protected against angiotensin II (Ang II)-induced mitochondrial dysfunction in the kidneys of mice. **a** Representative images of mitochondrial morphology in podocytes by electron microscopy. **b** qRT-PCR of the mtDNA copy number. Data are presented as means $\pm$ SE ($n = 8$). * $p < 0.05$ vs. vehicle group; # $p < 0.05$ vs. Ang II-treated group.

down of NLRP3 by a siRNA approach in podocytes remarkably mitigated the mitochondrial abnormalities. In animals, as expected, systemic deletion of NLRP3 also significantly attenuated mitochondrial dysfunction. These results suggest that Ang II-induced NLRP3 inflammasome activation could promote mitochondrial dysfunction in podocytes.

In addition, the blood pressure was similarly increased in WT and NLRP3^{-/-} mice after Ang II infusion, with no difference between genotypes, which is in agreement with the data reported by Wen et al. [28]. This result suggests that the attenuation of podocyte injury and mitochon-

drial dysfunction in NLRP3^{-/-} mice is independent of the hypertension effect.

In summary, in the present study, we presented new evidence showing that activation of the NLRP3 inflammasome mediated Ang II-induced podocyte injury, possibly through inducing mitochondrial dysfunction. Based on the importance of NLRP3 inflammasome activation in the development and progression of renal diseases, our findings emphasize the importance of targeting the NLRP3 inflammasome and/or mitochondria to develop novel strategies for the prevention and treatment of podocytopathy.

Acknowledgments

This work was supported by grants from the National Key Research and Development Program (No. 2016YFC0906103), the National Natural Science Foundation of China (No. 81530023, 81570616, and 81470928), and the Natural Science Foundation of Jiangsu Province (No. BK20141079 and BL2014007).

Statement of Ethics

All animal experiments were performed in accordance with the guidelines and regulations of the Animal Experimentation Ethics Committee of Nanjing Medical University. All experimental protocols were approved by the same committee.

Disclosure Statement

The authors have declared that no competing interest exists.

Author Contributions

M. Zhao and M. Bai performed the experiments and wrote the manuscript; G. Ding, Y. Zhang, S. Huang, and Z. Jia helped design the experiments and interpreted the data; A. Zhang designed the experiments, interpreted the data, wrote the manuscript, and approved the final version of the manuscript for publication.

References

- 1 Li XC, Zhang J, Zhuo JL: The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. *Pharmacol Res* 2017;125(pt A): 21–38.
- 2 Horita S, Nakamura M, Shirai A, Yamazaki O, Satoh N, Suzuki M, Seki G: Regulatory roles of nitric oxide and angiotensin II on renal tubular transport. *World J Nephrol* 2014;3:295–301.
- 3 Yang Y, Yang Q, Yang J, Ma Y, Ding G: Angiotensin II induces cholesterol accumulation and injury in podocytes. *Sci Rep* 2017;7: 10672.
- 4 Rizzo P, Novelli R, Rota C, Gagliardini E, Ruggiero B, Rottoli D, Benigni A, Remuzzi G: The role of angiotensin II in parietal epithelial cell proliferation and crescent formation in glomerular diseases. *Am J Pathol* 2017;187: 2441–2450.
- 5 Xu Z, Li W, Han J, Zou C, Huang W, Yu W, Shan X, Lum H, Li X, Liang G: Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). *Sci Rep* 2017;7: 44911.
- 6 Sharma R, Kinsey GR: Regulatory T cells in acute and chronic kidney diseases. *Am J Physiol Renal Physiol* 2017, Epub ahead of print.
- 7 Lee SB, Kalluri R: Mechanistic connection between inflammation and fibrosis. *Kidney Int Suppl* 2010;119:S22–S26.
- 8 Meng XM, Nikolic-Paterson DJ, Lan HY: Inflammatory processes in renal fibrosis. *Nat Rev Nephrol* 2014;10:493–503.
- 9 Lv LL, Liu BC: Role of non-classical renin-angiotensin system axis in renal fibrosis. *Front Physiol* 2015;6:117.
- 10 Tschopp J, Schroder K: NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? *Nat Rev Immunol* 2010;10:210–215.
- 11 Patel S: Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: a critical review with focus on NLRP3. *Biomed Pharmacother* 2017;92:819–825.
- 12 Zhuang Y, Ding G, Zhao M, Bai M, Yang L, Ni J, Wang R, Jia Z, Huang S, Zhang A: NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function. *J Biol Chem* 2014; 289:25101–25111.
- 13 Bai M, Chen Y, Zhao M, Zhang Y, He JC, Huang S, Jia Z, Zhang A: NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. *Am J Physiol Renal Physiol* 2017;312:F556–F564.
- 14 Liu D, Xu M, Ding LH, Lv LL, Liu H, Ma KL, Zhang AH, Crowley SD, Liu BC: Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. *Int J Biochem Cell Biol* 2014;57:7–19.
- 15 Fu R, Guo C, Wang S, Huang Y, Jin O, Hu H, Chen J, Xu B, Zhou M, Zhao J, Sung SJ, Wang H, Gaskin F, Yang N, Fu SM: Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. *Arthritis Rheumatol* 2017;69:1636–1646.
- 16 Che R, Yuan Y, Huang S, Zhang A: Mitochondrial dysfunction in the pathophysiology of renal diseases. *Am J Physiol Renal Physiol* 2014;306:F367–F378.
- 17 Yuan Y, Chen Y, Zhang P, Huang S, Zhu C, Ding G, Liu B, Yang T, Zhang A: Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. *Free Radic Biol Med* 2012;53:30–43.
- 18 Kadoguchi T, Kinugawa S, Takada S, Fukushima A, Furihata T, Homma T, Masaki Y, Mizushima W, Nishikawa M, Takahashi M, Yokota T, Matsushima S, Okita K, Tsutsui H: Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. *Exp Physiol* 2015; 100:312–322.
- 19 Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. *J Am Soc Nephrol* 1997;8:697–705.
- 20 Acton BM, Jurisicova A, Jurisica I, Casper RF: Alterations in mitochondrial membrane potential during preimplantation stages of mouse and human embryo development. *Mol Hum Reprod* 2004;10:23–32.
- 21 Greka A, Mundel P: Cell biology and pathology of podocytes. *Annu Rev Physiol* 2012;74: 299–323.
- 22 Urushihara M, Kagami S: Role of the intrarenal renin-angiotensin system in the progression of renal disease. *Pediatr Nephrol* 2017;32:1471–1479.
- 23 Della Penna SL, Rosón MI, Toblli JE, Fernández BE: Role of angiotensin II and oxidative stress in renal inflammation by hypernatremia: benefits of atrial natriuretic peptide, losartan, and tempol. *Free Radic Res* 2015;49: 383–396.
- 24 Chang A, Ko K, Clark MR: The emerging role of the inflammasome in kidney diseases. *Curr Opin Nephrol Hypertens* 2014;23:204–210.
- 25 Lorenz G, Darisipudi MN, Anders HJ: Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. *Nephrol Dial Transplant* 2014;29:41–48.
- 26 Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA: The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. *J Am Soc Nephrol* 2010;21:1732–1744.

- 27 Gong W, Mao S, Yu J, Song J, Jia Z, Huang S, Zhang A: NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy. *Am J Physiol Renal Physiol* 2016;310:F1081–F1088.
- 28 Wen Y, Liu Y, Tang T, Lv L, Liu H, Ma K, Liu B: NLRP3 inflammasome activation is involved in Ang II-induced kidney damage via mitochondrial dysfunction. *Oncotarget* 2016; 7:54290–54302.
- 29 Zhang GX, Lu XM, Kimura S, Nishiyama A: Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. *Cardiovasc Res* 2007;76:204–212.
- 30 Herrera M, Silva GB, Garvin JL: Angiotensin II stimulates thick ascending limb superoxide production via protein kinase Ca-dependent NADPH oxidase activation. *J Biol Chem* 2010;285:21323–21328.
- 31 Tsai IC, Pan ZC, Cheng HP, Liu CH, Lin BT, Jiang MJ: Reactive oxygen species derived from NADPH oxidase 1 and mitochondria mediate angiotensin II-induced smooth muscle cell senescence. *J Mol Cell Cardiol* 2016; 98:18–27.
- 32 Zhuang Y, Yasinta M, Hu C, Zhao M, Ding G, Bai M, Yang L, Ni J, Wang R, Jia Z, Huang S, Zhang A: Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury. *Am J Physiol Renal Physiol* 2015;308:F857–F866.